It’s a very exciting time to be part of the biopharmaceutical sector. The scientific innovation we are seeing, and helping to drive, is revolutionizing how certain diseases are diagnosed, treated and in some cases, cured. Precision medicine and breakthrough science including antibody-drug conjugates, immunotherapy and monoclonal antibodies are transforming how patients with chronic and fatal diseases are being treated around the world.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. For more information: www.astrazeneca.ca.
Consumer Health Products Canada is the industry association representing the companies that make evidence-based over-the-counter medicines and natural health products. These are the products you can find in medicine cabinets in every Canadian home. We work to shape a policy and regulatory environment that recognizes self-care as vital to the health of Canadians and the sustainability of our healthcare system. This ensures that Canadians have access to safe and effective products for their health.
CHP Canada’s members have a long history of advancing healthcare by developing products that allow Canadians to take better care of themselves. We are approaching an exciting point, where research and technology advancements are optimising health systems featuring self-care as one of the most innovative approaches to improving health coverage for all. We are confident that we can work with government and other stakeholders to advance self-care and support our member companies in their meaningful work for the everyday and long-term health of Canadians and the sustainability of our health care system.
Karen Proud, President, CHP Canada
Diabetes Canada is the registered national charitable organization that is making the invisible epidemic of diabetes visible and urgent. Diabetes Canada partners with Canadians to End Diabetes through:
- Resources for health-care professionals on best practices to care for people with diabetes;
- Advocacy to governments, schools and workplaces; and
- Funding world-leading Canadian research to improve treatments and find a cure.
Diabetes Canada is urging candidates in all parties to support the Diabetes 360° strategy to help urgently address the diabetes epidemic. For more information, visit diabetes.ca/strategy.
Canada continues to be without a nation-wide strategy to address the diabetes epidemic. The longer we delay implementing coordinated efforts with targeted outcomes, the more diabetes prevalence will increase and the more Canadians will experience its tragic complications. We urge all parties to support Diabetes 360˚ so Canada can be a world leader in the fight against this disease.
Dr. Jan Hux, President and CEO, Diabetes Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
The member companies of Innovative Medicines Canada have a strong history of success in discovering, developing and delivering medicines and vaccines that Canadians need to live healthy and productive lives. We have, over time and as a country, prioritized innovative health research within the health care system, with the effect of creating an environment that allows our best and brightest to do their complex and important work. We want to work with all levels of government will continue to support life sciences research in Canada through effective and thoughtful public policy. This includes developing policies and programs that ensure Canadians have access to new medicines, when they need them.
Pamela Fralick, President, Innovative Medicines Canada
AGE-WELL is a pan-Canadian network that brings together researchers, older adults, caregivers, future leaders with government, industry and community partners to accelerate the delivery of technology-based solutions that make a meaningful difference in the lives of Canadians. AGE-WELL researchers are producing technologies, services, and policies that improve quality of life for older adults and caregivers, and generate social and economic benefits for Canada. AGE-WELL is funded through the federal Networks of Centres of Excellence program.
At AGE-WELL, our focus is on helping older adults stay healthy and independent for as long as possible, while assisting those living with impairment and disability. We believe that technology can help all of us to age well but it is not enough. We need meaningful and sustained multi-sectoral partnerships to make a difference in the lives of Canadians.
Dr. Alex Mihailidis, Scientific Co-Director and CEO, AGE-WELL
As Canada’s leading mental illness research facility, CAMH aims to inspire hope through our groundbreaking discoveries. CAMH is working to revolutionize the understanding of the brain, use evidence to drive social change and optimize care, and inspire hope for those with mental illness. CAMH’s research programs and centres of innovation are leading studies that will help millions of people recover from depression, schizophrenia, bipolar disorder, dementia, addictions and more.
As Canada’s leading mental health research centre, CAMH aims to revolutionize the understanding mental illness. Through research, and continued investment in research, we want to do for mental illness what others have done for epilepsy, heart disease and cancer. We want to help people see mental health for what it really is—health.
Dr. Bruce Pollock, Vice President Research, CAMH
The Centre for Health Evaluation and Outcome Sciences (CHÉOS) produces the high-quality evidence needed to make informed changes to the health care system. Bridging the gap between data, research, and care, CHÉOS is a collaboration between cross-disciplinary scientists and expert research staff evaluating the effectiveness of health interventions at the population level. From assessing the cost effectiveness of a new drug or treatment option, to informing policy decisions that change how care is delivered, CHÉOS seeks to improve health outcomes for all with a focus on our most vulnerable populations.
Evidence is the most powerful tool in advancing health care, and to spark change we must connect research and real-world impact. That’s why at CHÉOS, we produce the high-quality evidence needed to create better health outcomes for Canadians. We must continue to work together, asking the relevant questions to address current gaps in knowledge while training the next generation of health researchers to push innovation even further.
Dr. Aslam Anis, Director, Centre for Health Evaluation and Outcome Sciences (CHÉOS)
Children’s Healthcare Canada is a national association representing health service delivery organizations serving children and youth across the continuum of care. Our membership includes tertiary acute care centres (children’s hospitals), rehabilitation and community hospitals serving children, home care and palliative care provider agencies. Through purposeful partnerships, we advance excellence and innovation in health systems caring for children and youth.
The Pediatric Chairs of Canada represent the Departments of Pediatrics within the seventeen Canadian medical schools. The Pediatric Chairs provide national leadership in research and education to promote the health and healthcare of children and youth in Canada.
Federal investments in health research not only contribute to a healthy vibrant population, they are drivers of Canada’s economy, fueling innovation and commercialization from coast to coast. Today in Canada, we understand that a limited portion of all health research dollars are targeted towards advancing health outcomes for children and youth who may suffer from rare disease, pediatric cancers, neurodevelopmental disabilities, or childhood asthma. The Pediatric Chairs of Canada and Children’s Healthcare Canada believe that investments in children’s health and health research are urgently required to reverse alarming trends in the health and wellbeing of children and youth in Canada.
Emily Gruenwoldt, President & CEO, Children′s Healthcare Canada and Executive Director, Pediatric Chairs of Canada
Concordia University is one of North America’s highest ranked universities founded in the last 50 years. Highly innovative, nimble and forward-thinking, Concordia defines and delivers next-generation teaching and research. Our community is a dynamic mix of faculty and students who research, create, teach, and engage across and beyond disciplines, making Concordia an international destination for leading thinkers. Deeply connected to Montreal and the world at large, we are a popular choice for more than 50,000 students across all major disciplines. Find out more at concordia.ca.
It is with great pleasure that Concordia University is participating in Research Canada’s Your Candidates, Your Health initiative. As a next-generation university committed to innovation and excellence in health research, we share Research Canada’s core values about the importance of promoting health research in all areas.
Dr. Christophe Guy, Vice-President, Research and Graduate Studies, Concordia University
For over a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.
Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
Merck Canada strongly believes that collaboration is the key to the future of innovation in the health sector. Industry and government have a shared responsibility to work together towards the common goal of building a robust healthcare environment that will provide meaningful benefit to Canadian patients.
Jennifer Chan, Vice-President, Policy and External Affairs, Merck Canada
The National Collaborating Centre for Methods and Tools (NCCMT) champions the use of evidence in public health. The NCCMT supports public health by compiling and sharing knowledge and high-quality resources on what works in public health. We also provide training and mentorship opportunities. Our goal is to facilitate optimal health and wellbeing for all Canadians by ensuring public health professionals have the knowledge and skills to implement the most effective and cost-efficient programs and services.
We believe that every Canadian has a fundamental right to experience optimal health and well-being. The National Collaborating Centre for Methods and Tools works collaboratively with the public health sector in Canada to ensure the most effective and cost-efficient programs are implemented so that optimal health and well-being are realized for all.
Dr. Maureen Dobbins, Scientific Director, NCCMT
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. @RocheCanada
Roche continues to grow its footprint in Canada with the establishment of four global hubs at our Mississauga site. This expansion is a testament to our skilled and talented workforce and offers tremendous opportunity to solidify Canada’s reputation as a life sciences hub.
Mr. Ronnie Miller, President and CEO, Hoffmann-La Roche Ltd.
Bausch Health Companies Inc. is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.
In Canada, Bausch Health’s prescription product portfolio is focused on eye health, dermatology and cardio-metabolic conditions. More information can be found at www.bauschhealth.ca.
With more than $4 billion in annual export value from its Canadian facilities and a global reputation for quality and innovation, Bausch Health, Canada remains focused on the development, distribution, and manufacturing of pharmaceutical products and technologies for Canadians, right here in Canada. Having manufacturing infrastructure in Canada allows for effective local production, resulting in faster access for patients.
Richard Lajoie, President and General Manager, Canada, Bausch Health
The Canadian Forum for Rare Disease Innovators (RAREi) is a group of the Canadian operation of global biopharmaceutical companies with a specific focus on researching, developing and commercializing treatments for rare diseases.
Canadians affected by rare diseases, many of whom are coping with severely debilitating or life threatening conditions, face many barriers to taking advantage of treatments. Our members are working to change that. Through our efforts to research and develop new therapies for rare diseases and support positive policy change, our goal is to bring new treatment options to the rare disease community in Canada.
Bob McLay, Chair, RAREi
McMaster University is Canada’s most research-intensive university and ranks second in the world for impact, based on Sustainable Development Goals of the United Nations. Our pioneering education advances and excellence in world-class research consistently place us among the top 50 universities in the world for health and medicine.
McMaster has longed been recognized as a global leader in health and life sciences innovations. Our research is strengthened by strong collaborations across our faculties and with our hospital partners. Our interdisciplinary approach to research positions us to tackle some of the most complex challenges of our time. Our infectious disease experts continue to translate their results into new products, changes in clinical practice and innovative policies; and our world leading cohort studies provide priceless data to maximize prevention, treatment and management of the most challenging chronic diseases.
Dr. Karen Mossman, Vice-President, Research (Acting), McMaster University
Shift Health brings a science mindset to strategy consulting for the health research and innovation ecosystem. We blend scientific depth, sector leadership and global perspective, tackling our clients’ most challenging questions with curiosity, rigour and courage. Delivering sharp insights and customized solutions, we’re helping to create the future of healthcare.
Canada is a nation of innovators. On a per capita basis, Canada boasts the fourth-largest science and technology workforce in the world—and nowhere is our heritage richer and our potential greater than in health research.
Dr. Ryan Wiley, President, Shift Health and Policy Advisor, Research Canada
For more than 50 years, the Canadian Nurses Foundation has helped nurses learn, investigate and advance nursing best practices. CNF awards scholarships to promising nursing students and nurses across the country at all educational levels, and funds nursing research that enhances the quality and efficacy of patient care.
CNF believes that with the significant trends and pressures in our health care system, it becomes paramount that nursing research continues to be undertaken by nurses in collaboration with other health professionals to improve quality of life and care of Canadian patients, families, and communities. Investigating and advancing innovative health-care, while providing the groundwork for future practice-based research studies, is essential for a healthy Canada.
Christine Rieck Buckley, Chief Executive Officer, Canadian Nurses Foundation
Click here to watch parts 2 and 3 of Natania’s story.
The Lady Davis Institute (LDI) is the research arm of the Jewish General Hospital, with strong academic ties to McGill University. The Institute has earned an international reputation for its research programs in cancer, clinical epidemiology, molecular and regenerative medicine, and the psychosocial aspects of disease. Since its founding in 1969, LDI scientists have pursued the mission of bringing benefits to the health and well-being of patients.
Research represents hope for everyone who ever has faced, or ever will face, the prospect of a major illness. Our objective at the Lady Davis Institute, which we share with Research Canada, is to advance science in order to improve the quality of life and outcomes for patients. Our researchers and clinicians work in a continuous feedback loop to translate knowledge from the bench to the bedside and back in furtherance of those objectives.